Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicines Company Gets Aggressive With Inclisiran Phase III Plans

Executive Summary

Updated ORION-1 data presented at the European Society of Cardiology have encouraged The Medicines Company to take an "aggressive" approach to its Phase III plans for the novel PCSK9 synthesis inhibitor.

Advertisement

Related Content

The Medicines Co. Names Mark Timney As CEO In A Shakeup
Making Real World Evidence Less 'Messy' To Help With Drug Pricing
Melinta Expands Portfolio, TMC Narrows Focus To LDL Reduction With Anti-Infective Deal
Life In The Old Dog Yet: Growth In Dyslipidemia Market Expected To 2025
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099400

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel